Glen Eagle Advisors’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $339 | Buy |
+5
| New | +$125 | ﹤0.01% | 1069 |
|
|
2025
Q3 | – | Sell |
-17
| Closed | -$208 | – | 1123 |
|
|
2025
Q2 | $208 | Hold |
17
| – | – | ﹤0.01% | 1015 |
|
|
2025
Q1 | $244 | Hold |
17
| – | – | ﹤0.01% | 1029 |
|
|
2024
Q4 | $271 | Hold |
17
| – | – | ﹤0.01% | 1053 |
|
|
2024
Q3 | $409 | Hold |
17
| – | – | ﹤0.01% | 1079 |
|
|
2024
Q2 | $339 | Hold |
17
| – | – | ﹤0.01% | 1083 |
|
|
2024
Q1 | $338 | Hold |
17
| – | – | ﹤0.01% | 1045 |
|
|
2023
Q4 | $381 | Hold |
17
| – | – | ﹤0.01% | 980 |
|
|
2023
Q3 | $344 | Hold |
17
| – | – | ﹤0.01% | 983 |
|
|
2023
Q2 | $435 | Sell |
17
-3
| -15% | -$79 | ﹤0.01% | 1010 |
|
|
2023
Q1 | $595 | Buy |
20
+3
| +18% | +$87 | ﹤0.01% | 993 |
|
|
2022
Q4 | $460 | Hold |
17
| – | – | ﹤0.01% | 1089 |
|
|
2022
Q3 | $370 | Hold |
17
| – | – | ﹤0.01% | 1037 |
|
|
2022
Q2 | $465 | Hold |
17
| – | – | ﹤0.01% | 946 |
|
|
2022
Q1 | $570 | Hold |
17
| – | – | ﹤0.01% | 899 |
|
|
2021
Q4 | $589 | Hold |
17
| – | – | ﹤0.01% | 883 |
|
|
2021
Q3 | $530 | Hold |
17
| – | – | ﹤0.01% | 1013 |
|
|
2021
Q2 | $618 | Hold |
17
| – | – | ﹤0.01% | 991 |
|
|
2021
Q1 | $744 | Hold |
17
| – | – | ﹤0.01% | 953 |
|
|
2020
Q4 | $780 | Hold |
17
| – | – | ﹤0.01% | 921 |
|
|
2020
Q3 | $565 | Buy |
+17
| New | +$543 | ﹤0.01% | 876 |
|
Other funds holding AVNS
Glen Eagle Advisors's AVNS Position: Q3 2026 in Review
Glen Eagle Advisors opened a new position in Avanos Medical (AVNS) in Q3 2026: 5 shares worth $339. The stake represents ﹤0.01% of the portfolio and ranks #1069 among its holdings. This is a return to the name: Glen Eagle Advisors previously reported a position in AVNS as recently as Q2 2025.
Glen Eagle Advisors first reported a position in AVNS in Q3 2020 and has held it in 21 quarters since. The position peaked at $780 in Q4 2020. 4 funds tracked by Wall St. Rank hold AVNS as of Q3 2026.
- Glen Eagle Advisors held 5 shares of Avanos Medical worth $339 as of Q3 2026.
- Avanos Medical was a new Glen Eagle Advisors position in Q3 2026.
- Avanos Medical made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q3 2026, its #1069 holding.
- Glen Eagle Advisors first reported a position in Avanos Medical in Q3 2020 and has held it in 21 quarters since.
- Glen Eagle Advisors's Avanos Medical position peaked at $780 in Q4 2020.
- 4 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2026.
Based on Glen Eagle Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.